Literature DB >> 21075782

Epigenetic regulation of glial fibrillary acidic protein by DNA methylation in human malignant gliomas.

Andres Restrepo1, Christian A Smith, Sameer Agnihotri, Maryam Shekarforoush, Paul N Kongkham, Ho Jun Seol, Paul Northcott, James T Rutka.   

Abstract

Glial fibrillary acidic protein (GFAP) is an intermediate filament expressed in glial cells that stabilizes and maintains the cytoskeleton of normal astrocytes. In glial tumors, GFAP expression is frequently lost with increasing grade of malignancy, suggesting that GFAP is important for maintaining glial cell morphology or regulating astrocytoma cell growth. Most permanent human glioma cell lines are GFAP negative by immunocytochemistry. Given that the GFAP gene is not mutated in human glioma specimens or glioma cell lines, we considered epigenetic mechanisms, such as promoter methylation, as a cause of silencing of GFAP in these tumors. In this study, we treated known GFAP-negative glioma cell lines with 5-aza-2'-deoxycytidine to examine GFAP promoter hypermethylation. Additionally, we performed bisulfite sequencing on primary glioma samples and glioma cell lines and showed an inverse relationship between GFAP promoter methylation status and GFAP expression. Using a gene reporter assay with the GFAP promoter cloned upstream of a luciferase gene, we showed that methylation of the GFAP promoter downregulates the expression of the luciferase gene. Our results suggest that epigenetic silencing of the GFAP gene through DNA methylation of its promoter region may be one mechanism by which GFAP is downregulated in human gliomas and glioma cell lines.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21075782      PMCID: PMC3018916          DOI: 10.1093/neuonc/noq145

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  34 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  The role of glial fibrillary acidic protein in the diagnosis of central nervous system tumors.

Authors:  J H Deck; L F Eng; J Bigbee; S M Woodcock
Journal:  Acta Neuropathol       Date:  1978-06-30       Impact factor: 17.088

3.  DNA methylation is a critical cell-intrinsic determinant of astrocyte differentiation in the fetal brain.

Authors:  T Takizawa; K Nakashima; M Namihira; W Ochiai; A Uemura; M Yanagisawa; N Fujita; M Nakao; T Taga
Journal:  Dev Cell       Date:  2001-12       Impact factor: 12.270

4.  Glial fibrillary acidic protein in giant cell tumors of brain and other gliomas. A possible relationship to malignancy, differentiation, and pleomorphism of glia.

Authors:  P E Duffy; Y Y Huang; M M Rapport; L Graf
Journal:  Acta Neuropathol       Date:  1980       Impact factor: 17.088

5.  Immunolocalization of fascin, an actin-bundling protein and glial fibrillary acidic protein in human astrocytoma cells.

Authors:  Soma Mondal; Peter Dirks; James T Rutka
Journal:  Brain Pathol       Date:  2009-01-15       Impact factor: 6.508

6.  Expression of glial fibrillary acidic protein in primary cultures of human Müller cells.

Authors:  Caroline Lupien; Michael Brenner; Sylvain L Guérin; Christian Salesse
Journal:  Exp Eye Res       Date:  2004-09       Impact factor: 3.467

7.  An epigenetic genome-wide screen identifies SPINT2 as a novel tumor suppressor gene in pediatric medulloblastoma.

Authors:  Paul N Kongkham; Paul A Northcott; Young Shin Ra; Yukiko Nakahara; Todd G Mainprize; Sidney E Croul; Christian A Smith; Michael D Taylor; James T Rutka
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

8.  Expression of fascin, an actin-bundling protein, in astrocytomas of varying grades.

Authors:  Aurelia Peraud; Soma Mondal; Cynthia Hawkins; Michelle Mastronardi; Kristy Bailey; James T Rutka
Journal:  Brain Tumor Pathol       Date:  2003       Impact factor: 3.298

9.  Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease.

Authors:  M Brenner; A B Johnson; O Boespflug-Tanguy; D Rodriguez; J E Goldman; A Messing
Journal:  Nat Genet       Date:  2001-01       Impact factor: 38.330

10.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Authors: 
Journal:  Nature       Date:  2008-09-04       Impact factor: 49.962

View more
  16 in total

1.  Definition of genetic events directing the development of distinct types of brain tumors from postnatal neural stem/progenitor cells.

Authors:  Falk Hertwig; Katharina Meyer; Sebastian Braun; Sara Ek; Rainer Spang; Cosima V Pfenninger; Isabella Artner; Gaëlle Prost; Xinbin Chen; Jaclyn A Biegel; Alexander R Judkins; Elisabet Englund; Ulrike A Nuber
Journal:  Cancer Res       Date:  2012-06-20       Impact factor: 12.701

2.  Oncogenic KRAS promotes malignant brain tumors in zebrafish.

Authors:  Bensheng Ju; Wenbiao Chen; Brent A Orr; Jan M Spitsbergen; Sujuan Jia; Christopher J Eden; Hannah E Henson; Michael R Taylor
Journal:  Mol Cancer       Date:  2015-02-03       Impact factor: 27.401

Review 3.  Comorbidities in Neurology: Is adenosine the common link?

Authors:  Detlev Boison; Eleonora Aronica
Journal:  Neuropharmacology       Date:  2015-05-13       Impact factor: 5.250

4.  P2X7 receptor antagonism inhibits tumour growth in human high-grade gliomas.

Authors:  Liyen Katrina Kan; Sinali Seneviratne; Kate J Drummond; David A Williams; Terence J O'Brien; Mastura Monif
Journal:  Purinergic Signal       Date:  2020-06-24       Impact factor: 3.765

5.  E804 induces growth arrest, differentiation and apoptosis of glioblastoma cells by blocking Stat3 signaling.

Authors:  Yanmin Zhang; Zhaoxiao Du; Zirong Zhuang; Yanjun Wang; Fen Wang; Shuai Liu; Han Wang; Hairong Feng; Haoyuan Li; Liyan Wang; Xianghong Zhang; Aijun Hao
Journal:  J Neurooncol       Date:  2015-09-19       Impact factor: 4.130

Review 6.  Deregulated chromatin remodeling in the pathobiology of brain tumors.

Authors:  Anastasia Spyropoulou; Christina Piperi; Christos Adamopoulos; Athanasios G Papavassiliou
Journal:  Neuromolecular Med       Date:  2013-03       Impact factor: 3.843

7.  Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide.

Authors:  Alex Shimura Yamashita; Marina da Costa Rosa; Alexandra Borodovsky; William T Festuccia; Timothy Chan; Gregory J Riggins
Journal:  Neuro Oncol       Date:  2019-02-14       Impact factor: 12.300

8.  Genetic background affects human glial fibrillary acidic protein promoter activity.

Authors:  Xianshu Bai; Aiman S Saab; Wenhui Huang; Isolde K Hoberg; Frank Kirchhoff; Anja Scheller
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

9.  A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas.

Authors:  Sameer Agnihotri; Amparo Wolf; Diana M Munoz; Christopher J Smith; Aaron Gajadhar; Andres Restrepo; Ian D Clarke; Gregory N Fuller; Santosh Kesari; Peter B Dirks; C Jane McGlade; William L Stanford; Kenneth Aldape; Paul S Mischel; Cynthia Hawkins; Abhijit Guha
Journal:  J Exp Med       Date:  2011-04-04       Impact factor: 14.307

10.  Type 1 equilibrative nucleoside transporter regulates astrocyte-specific glial fibrillary acidic protein expression in the striatum.

Authors:  David J Hinton; Moonnoh R Lee; Jin Sung Jang; Doo-Sup Choi
Journal:  Brain Behav       Date:  2014-09-19       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.